Product candidate
Discovery
In vivo PoC
Phase 1
Phase 2
Phase 3 / pivotal
Milestones
2H 2023In vivo proof-of-concept data
Solid tumors circAde
circVec
circRNA vector
2H 2023In vivo proof-of-concept data
Infectious disease, circVac
2H 2023Target screening and selection
Rare disease
ONCOS-102
mRNA vector1
TBD 2023-24
Initiation of phase 2 trial (USA)
PD-1 Resistant Melanoma Re-challenge combination w/aPD-1 & CTLA-4
Mutant KRAS1
1H 2023
First patient dosed (USA & EU)
Pancreatic cancer & Multiple Myeloma TG01/QS-21 +/- anti-PD-1
Cancer Indication: Solid tumors circAde
Product candidate: circVec circRNA vector
Next expected event: 2H 2023
In vivo proof-of-concept data
Discovery
In vivo PoC
Phase 1
Phase 2
Phase 3 / pivotal
Cancer Indication: Infectious disease, circVac
Product candidate: circVec circRNA vector
Next expected event: 2H 2023
In vivo proof-of-concept data
Discovery
In vivo PoC
Phase 1
Phase 2
Phase 3 / pivotal
Cancer Indication: Rare disease
Product candidate: circVec circRNA vector
Next expected event: 2H 2023
Target screening and selection
Discovery
In vivo PoC
Phase 1
Phase 2
Phase 3 / pivotal
Cancer Indication: PD-1 Resistant Melanoma
Combination with: Re-challenge combination w/aPD-1 & CTLA-4
Product candidate: ONCOS-102 mRNA vector1
Next expected event: TBD 2023-24
Initiation of phase 2 trial (USA)
Discovery
In vivo PoC
Phase 1
Phase 2
Phase 3 / pivotal
Cancer Indication: Pancreatic cancer & Multiple Myeloma
Combination with: TG01/QS-21 +/- anti-PD-1
Product candidate: Mutant KRAS1
Next expected event: 1H 2023
First patient dosed (USA & EU)
Discovery
In vivo PoC
Phase 1
Phase 2
Phase 3 / pivotal
Two trials run and financed by collaboration partners
1Pending additional financing or partnership